TISA-818, an Anti-inflammatory Conjugate of Montelukast-Decapeptide, in Acute Respiratory Distress Syndrome Due to Pulmonary Infection: A Phase 2 Randomized Trial Using the 2023 Global Definition.

Authors

Linna Huang, Xu Huang, Feifei Jiao, Bing Sun, Xiaoli Han, Wancang Jiang, Weiwen Zhang, Hong Luo, Lingling Su, Ming Gu, Jun He, Longlong Jiao, Xiao Tang, Lei Jiang, Danqiong Wang, Min Yang, Xianghong Yang, Dan Li, Huaxue Wang, Xiaoliang Yuan, Hai Lin, Ziqiang Shao, Kun Lu, Bailing Yan, Yongmei Zhang, Kuan Liu, Anders Kärnell, Qingyuan Zhan

Published in

Chest. Oct 03, 2026. Epub Oct 03, 2026.

Abstract

Acute respiratory distress syndrome (ARDS) remains associated with substantial mortality. The 2023 global definition includes non-intubated patients, creating an opportunity to evaluate therapies earlier in the disease course.
Is TISA-818 safe and potentially efficacious in patients with ARDS, particularly those who are non-intubated?
This randomized, double-blind, placebo-controlled, multicenter phase 2 trial was, to our knowledge, the first in China to use the 2023 global ARDS definition. Fifty-eight patients were randomized 1:1:1 to intravenous TISA-818 6 mg twice daily (BID), 12 mg once daily (QD), or matched placebo for 14 days. The primary endpoint was safety. Key secondary endpoints included respiratory support-free days (RSFDs) through day 28, proportion of patients alive and free from respiratory support at day 14, clinical improvement rate at day 14, and length of stay through 28 days.
TISA-818 demonstrated an acceptable safety profile with comparable rates of treatment-emergent adverse events (AEs) and no unexpected safety signals. Treatment-related AEs were mild-to-moderate and occurred in 5.3%, 36.8%, and 21.1% of patients in the placebo, 6 mg BID, and 12 mg QD groups, respectively. Day-28 mortality was 5.3%, 10.5%, and 26.3%, whereas day-60 mortality was 26.3%, 21.1%, and 31.6% for placebo, 6 mg BID, and 12 mg QD, respectively. No drug-related serious AEs or deaths occurred. In the prespecified non-intubated subgroup (n=27, 9 per arm), exploratory analyses numerically favored 6 mg BID over placebo, with more RSFDs (difference, 6 days; 95% confidence interval, -3 to 15) and consistent numerical improvements across all secondary outcomes.
TISA-818 was generally well tolerated. Day-28 mortality was numerically imbalanced but not sustained, likely reflecting small-sample variability; cautious interpretation is warranted. Consistent improvements across all efficacy endpoints, particularly with 6 mg BID in non-intubated patients, support further investigation in adequately powered trials.

PMID:
42829168
Bibliographic data and abstract were imported from PubMed on 04 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.